Efficacy, Safety, and Prognosis of Multiple Treatment Modalities for Head and Neck Malignant Tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600123756

Enrollment

Unknown

Registered

2026-04-29

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck malignant tumors

Interventions

PD-1 inhibitor combined with intra-arterial infusion chemotherapy group and intravenous chemotherapy group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18; any gender 2.Patients diagnosed with head and neck malignant tumors by pathology who visited Ganzhou People's Hospital between January 2019 and September 2025, with objective measurable lesion size and quantity confirmed by CT and MRI imaging; 3.Received surgical treatment and/or chemotherapy, targeted therapy, or immunotherapy; 4.Able to attend regular follow-up visits;

Exclusion criteria

Exclusion criteria: 1.Patients with severe infection or psychiatric disorders; 2.Patients unable to complete radiotherapy and chemotherapy; 3.Patients with immune system diseases or receiving immunotherapy; 4.Patients with head and neck malignant tumors deemed unsuitable for this study by the investigator;

Design outcomes

Primary

Measure	Time frame
Overall Survival,Progression-Free Survival;	—

Countries

China

Contacts

Public ContactPeng Yonghua

Ganzhou People's Hospital

365863127@qq.com+86 797 5889290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026